ClinicalTrials.Veeva

Menu

A Single-blind, Randomized, Controlled Clinical Study of Flash Stimulation Therapy in Parkinson's Disease

Zhejiang University logo

Zhejiang University

Status

Not yet enrolling

Conditions

Parkinson's Disease

Treatments

Device: 40Hz light modulation glasses
Device: 100Hz light modulation glasses

Study type

Interventional

Funder types

Other

Identifiers

NCT06848621
2024-1021

Details and patient eligibility

About

The aim of this study was to evaluate the effect of flash stimulation therapy on the function of the cerebral glymphatic system and efficacy of improving symptoms in PD patients.

Full description

Each subject will receive EEG recordings for two consecutive nights starting at 21:00. Participants will undergo baseline functional magnetic resonance imaging (fMRI). Subsequently, one week of flash stimulation therapy (JK-PMEG2700K light modulation glasses [light source]) was started, using flash stimulation between 20:00 and 21:00. After the 7-day flash stimulation treatment, a second round of clinical evaluation and fMRI will be performed.

Enrollment

48 estimated patients

Sex

All

Ages

50 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. PD patients who meet the diagnostic criteria of the International Movement Disorders Association (MDS), between the ages of 50 and 70 years, the course of disease ≤5 years, and the Hoehn & Yahr stage ≤3;
  2. Anti-PD drugs were taken regularly for at least one month before screening, and symptoms were stable;
  3. The fixed bedtime in the past month is between 9:00 p.m. and 1:00 a.m., and the total sleep time is ≥6 hours;
  4. Have the ability to understand and voluntarily sign informed consent;
  5. Have good compliance and are willing to complete all follow-up required by this program.

Exclusion criteria

  1. Secondary insomnia: including sleep disorders (restless leg syndrome, periodic limb movement disorder, sleep-related breathing disorders, etc.), physical diseases, mental disorders, psychoactive substance abuse;
  2. suffering from photosensitive dermatitis, epilepsy and other diseases that are not suitable for flash stimulation;
  3. Alcohol, coffee, or drug abusers in the past 6 months;
  4. Mental illness: such as anxiety, depression, schizophrenia and post-traumatic stress disorder caused by insomnia;
  5. Used drugs or health products that regulate sleep function or affect sleep within 14 days before enrollment or less than 5 drug half-lives;
  6. Taking drugs that may impair cognitive ability, such as anticholinergic drugs, memory enhancing drugs, etc., within 7 days before enrollment;
  7. the subject is unable to complete the test or follow-up;
  8. suffering from other neurodegenerative diseases;
  9. There are endoplants in the body that cannot be examined by MRI;
  10. Inability to lie flat;
  11. Other situations in which the researcher considers it inappropriate to participate in the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

48 participants in 2 patient groups

Group1:40Hz flash stimulation
Experimental group
Description:
A one-week 40HZ flash stimulation therapy (JK-PMEG2700K light modulation glasses \[light source\]) using flash stimulation between 20:00 and 21:00.
Treatment:
Device: 40Hz light modulation glasses
Group2:100Hz flash stimulation
Sham Comparator group
Description:
A one-week 100HZ flash stimulation therapy (JK-PMEG2700K light modulation glasses \[light source\]) using flash stimulation between 20:00 and 21:00.
Treatment:
Device: 100Hz light modulation glasses

Trial contacts and locations

1

Loading...

Central trial contact

baorong zhang, Doctor; yang ruan, Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems